Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammatory markers with preserved versus non-preserved topical anti-glaucoma eye drops
2013-000581-10Phase 4Completed
- Sponsor
- Nottingham University Hospitals
- Start
- Apr 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of latanoprost, travoprost, bimatoprost, tafluprost, timolol and 4 more in Glaucoma and ocular hypertension (2 arms), sponsored by Nottingham University Hospitals. Primary endpoint: Biomarker change on the ocular surface. Started Apr 2013; status: completed.
02
Drugs
latanoprosttravoprostbimatoprosttafluprosttimolol
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2013-000581-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000581-10.